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Abstract
Background: Key stakeholders regard generic utility instruments as suitable tools to inform health technology
assessment decision-making regarding allocation of resources across competing interventions. These instruments
require a ‘descriptor’,a‘valuation’ and a ‘perspective’ of the economic evaluation. There are various approaches
that can be taken for each of these, offering a potential lack of consistency between instruments (a basic
requirement for comparisons across diseases). The ‘reference method’ has been proposed as a way to address the
limitations of the Quality-Adjusted Life Year (QALY). However, the degree to which generic measures can assess
patients’ specific experiences with their disease would remain unresolved. This has been neglected in the
discussions on methods development and its impact on the QALY values obtained and resulting cost per QALY
estimate underestimated. This study explored the content of utility instruments relevant to type 2 diabetes and
Alzheimer’s disease (AD) as examples, and the role of qualitative research in informing the trade-off between
content coverage and consistency.
Method: A literature review was performed to identify qualitative and quantitative studies regarding patients’
experiences with type 2 diabetes or AD, and associated treatments. Conceptual models for each indication were
developed. Generic- and disease-specific instruments were mapped to the conceptual models.
Results: Findings showed that published descriptions of relevant concepts important to patients with type 2
diabetes or AD are available for consideration in deciding on the most comprehensive approach to utility
assessment. While the 15-dimensional health related quality of life measure (15D) seemed the most comprehensive
measure for both diseases, the Health Utilities Index 3 (HUI 3) seemed to have the least coverage for type 2
diabetes and the EuroQol-5 Dimensions (EQ-5D) for AD. Furthermore, some of the utility instruments contained
items that could not be mapped onto either of the proposed conceptual models.
Conclusions: Content of the utility measure has a significant impact on the treatment effects that can be
observed. This varies from one disease to the next and as such contributes to lack of consistency in observable
utility effects and incremental utility scores. This observation appears to have been omitted from the method
development considerations such as reference methods. As a result, we recommend that patients’ perspectives
obtained via qualitative methods are taken into consideration in the ongoing methods development in health
state descriptions for generic utility instruments. Also, as a more immediate contribution to improving decision
making, we propose that a content map of the chosen utility measure with patient-reported domains be provided
as standard reporting in utility measurement in order to improve the transparency of the trade-offs in relation to
patient relevance and consistency.
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National, regional and local decision makers have to
determine how best to allocate scarce resource so as to
obtain optimum benefit [1]. The Quality-Adjusted Life
Year (QALY) is a concept used to facilitate decision
making in that it is intended to allow comparison of
health effects across different diseases [2].
In the United Kingdom, The National Institute for
Health and Clinical Excellence (NICE) guidance clearly
states that for cost effectiveness analysis, the value of
health effects should be expressed in terms of QALYs
and the measurement of changes in health-related qual-
ity of life (HRQoL) should be reported directly from
patients. Although the NICE guidelines state the use of
disease-specific preference based measures may be con-
sidered if they are justified, the value of changes in
patients’ HRQoL (that is, utilities) should be based on
public preferences using a choice-based method [3].
The equivalent body for Scotland, Scottish Medicine
Consortium (SMC), also prefer the QALY and consider
it to be the most appropriate generic assessment of
health benefit that reflects both mortality and HRQoL
effects, and which allows comparisons between interven-
tions [4]. Likewise, reimbursement bodies in Sweden,
the Netherlands and Canada all clearly specify QALYs
as the preferred method [5-7].
QALYs are calculated by estimating the total life years
gained from a treatment and then weighting each year
with a score. This score ranges from 0 to 1 (or 100) repre-
senting ‘worst imaginable health’ and ‘best health’ respec-
tively. The utility is considered reflective of HRQoL in that
year. The fundamental idea is that an extra year in good
health does not have the same value to patients as a year
in poor health [8]. The number of QALYs are then
expressed as the value given to a particular health state
multiplied by the period of time spent in that state to
determine a composite measure of health [9].
This process requires a descriptor, a valuation, and a
perspective for the utility measurement. There are various
approaches that can be taken for each of these. For exam-
ple, a descriptor method is a description of health and its
impact on HRQoL and can be developed using clinicians,
patients, or people from the general population (or even a
combination of these). The descriptor method can also be
presented in different ways such as using a vignette or the
EuroQol-5 Dimensions (EQ-5D) items. A valuation
method refers to a value given to a health state description
such as using a visual analogue scale or standard gamble,
and a perspective can range from for example the health-
care provider or a societal perspective. The diverse
approaches for descriptors, valuations and perspectives
may contribute to a lack of consistency and diversity in
scores, making consistent decision making more difficult.
Utility instruments incorporate preferences or values
attached to individual health states and express health
states as a single index. They can be classified as generic
and therefore suitable for use in various populations and
disease-specific populations, allowing decision makers to
make comparisons. Examples of generic utility measures
include the EQ-5D, the Health Utilities Index (HUI)
[10], the 15-dimensional health related quality of life
measure (15-D) [11] and the Medical Outcomes Study
Health Survey (MOS SF-6D) [12]. The NICE guidelines
specify that the (EQ-5D) is the preferred measure of uti-
lities in adults [13].
Disease-specific instruments are developed to measure
the patients’ perceptions and HRQoL impact of a speci-
fic disease or health problem. The main advantages of
disease-specific measures are that they tend to be rele-
vant to the impact of a specific disease on patients, and
clinicians find them useful [14]. In addition, in longitu-
dinal studies, disease-specific instruments are more
likely to be responsive to clinical changes since the
issues assessed are so relevant to the condition [15].
However, the very nature of the measures being disease
specific limits the ability to compare values across dis-
ease areas. Disease-specific utility instruments do not
contain any items or health dimensions that are not
relevant to the disease; these instruments have clear
relevance to patients with the presenting problem and
thus acceptability is likely to be high. Regulatory bodies
such as Food and Drug Administration (FDA) and Eur-
opean Medicines Agency (EMA) have stated preferences
for disease-specific measures which can show sensitivity
in specific disease areas due to their relevance to
patients and those who treat them; currently generic
measures do not have this level of sensitivity for indivi-
dual diseases. Thus, there is some degree of disconnect
between regulatory bodies (such as FDA and EMA) and
health technology bodies such as NICE or SMC. Oppor-
tunities to harmonize or integrate these methods could
provide positive steps in reconciling and interpreting the
different needs of decision makers.
Regulatory authorities such as the FDA and EMA have
endorsed patient-reported outcomes and emphasised the
need to take the patient perspective into account when
developing an instrument, particularly aspects of
HRQoL [16,17].
The recent special issue of the Value in Health sum-
marising the ISPOR Consensus Development Workshop
focuses on “moving the QALY forward” with emphasis
on “how to define and refine the QALY” as a standard
metric [18]. It is generally recognised that the sensitivity
of the QALY can vary across different disease areas [4],
that different methods of utility measurement yield dif-
ferent results and there is no clear consensus as to
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citation [19]; although NICE have opted for the EQ-5D
as a preferred instrument.
It was recently highlighted at the QALY development
workshop that the absence of a better alternative makes
the QALY an indispensable tool [20]. These generic
instruments currently have a pivotal role in healthcare
technology decision making in some countries and the
outcome of such decisions that directly influence
patients and carers.
One possible solution to developing a preferred
approach is a ‘reference method’ [21] where a standar-
dised approach (to descriptor, valuation method) would
be proposed for all economic evaluations; while simulta-
neously not excluding other approaches. Although this is
a theoretically appropriate approach, it is not yet clear
how a reference method would be derived. It is also
acknowledged that even if this was achieved, if a single
measure was chosen, it could bias the allocation of
resources in favour of some diseases or interventions that
have impact on the particular attributes of that measure.
This could be reduced by proposing an approach that
included more than one measure but this was identified
as being more costly. Qualitative methods could be help-
ful in deciding what should be encompassed in a “refer-
ence descriptor” as well as understanding the trade-off
between content and ability to compare across diseases
of the current utility descriptors.
The broad objective of this study was to assess how
qualitative methods can improve knowledge about which
current utility instruments assess concepts of relevance
from the patients’ perspective. Alzheimer’s disease and
type 2 diabetes were used as examples of diseases that
are prevalent and represented in the general population.
Methods
A literature review was performed in two parts. The aim
of part one was to identify patient qualitative research
in the two diseases of interest (type 2 diabetes and AD).
The focus was to gain an understanding of the symp-
toms and subjective experiences of patients with type 2
diabetes and those with AD. Part two aimed to identify
generic and disease-specific utility instruments used in
type 2 diabetes and AD. The analysis then compared
the relevant domains for the diseases with the construc-
tion and validation of the instruments.
Literature Review Part I: Qualitative Research
A search strategy was implemented using electronic
databases (PUBMED, PsycINFO, and Embase) to iden-
tify relevant qualitative studies from January 2003 to
October 2008, using the search terms presented in
Table 1. The review was limited to English language stu-
dies and human subjects.
On completion of the search all titles and abstracts
were screened for possible inclusion in the study by two
independent researchers. Disagreements were resolved
by subsequent discussion with another researcher who
performed an independent review and made a final
decision.
To satisfy the inclusion criteria, selected abstracts had
to include an appropriate clinical term related to one of
the relevant indications (e.g. Diabetes mellitus, type 2
[MeSH Terms]), at least one patient-reported outcome
term (e.g. quality of life), and at least one methodologi-
cal term (e.g. qualitative research [MeSH Terms]) in the
title or abstract.
Abstracts were excluded if they were primarily clinical,
economic or quantitative in focus, the perspective was
not patient focused (e.g. caregiver or health-care profes-
sional), or the abstract did not refer to a journal article
(e.g. letters, conferences, dissertations, books or
chapters).
Following pre-testing, data extraction tables were fina-
lised to accurately extract information on the symptoms
and subjective experiences of patients including patient
quotes where relevant. A thematic analysis was per-
formed on the patient quotes [22]. Each data item
within each quote was examined repeatedly and was
given equal attention during the coding process, which
was thorough, inclusive and as comprehensive as possi-
ble. The coding process was performed without trying
to fit it into a pre-existing coding frame. Rather, the
relevant extracts from the dataset were collated to form
Table 1 Search Terms
Terms Keywords Command
1. Indication* Alzheimer’s Disease [MeSH Terms] OR Diabetes mellitus, type 2 [MeSH Terms] AND
2. Patient Reported
Outcome (PRO)
Health-Related Quality of Life OR HRQoL OR hrqlOR quality of life [MeSH Terms] OR QoL OR signs and
symptoms [MeSH Terms] OR emotions [MeSH Terms] OR physical OR psychological OR psychosocial OR
impact OR relationships OR family impact OR work [MeSH Terms] OR productivity OR absenteeism [MeSH
Terms] OR presenteeism
AND
3. Method Qualitative research [MeSH Terms] OR interviews as topic [MeSH Terms] OR narration [MeSH Terms]OR
interview, psychological [MeSH Terms] OR grounded theory OR interpretive phenomenological analysis OR
focus groups
* Searches for each indication were performed independently.
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and against the original dataset to ensure that they were
coherent, consistent, and distinctive. The process was
predominantly inductive in that the themes identified
were strongly linked to the data themselves, and thus
data driven. Also, the themes were semantic themes
identified within the explicit or surface meanings of the
data, and the researcher was not looking for anything
beyond what a patient said. However, there was gradual
progression from description whereby the data were
organised and summarised to show patterns, to an inter-
pretative process to attempt to theorise on the signifi-
cance of the patterns and their broader meanings and
implications. The extracts were also checked to ensure
that they matched the analytic claims. Following the-
matic analyses, conceptual models were developed for
each indication to provide a visual representation of the
key themes and how they appear to be related to each
other.
Literature Review Part II: Utility Measures
To identify utility studies, an additional search strategy
was implemented from August 2006 to October 2008
using PUBMED, utilising the same indications as in
Table 1, and a search for the following terms: utilities
OR utility OR QALY [MeSH Terms]. To satisfy the
inclusion criteria, papers had to include an appropriate
clinical term and reference to a utility measure in the
title or abstract. Limits and exclusions were similar to
part one of the literature review. The extent to which
patients and healthy people were involved in their devel-
opment was considered. The utility instruments were
then assessed for their relevance to the diabetes and AD
populations.
Mapping Utility Instruments to Proposed Conceptual
Models
Each item (question) of utility instruments identified
from part two of the literature review was then mapped
on to the conceptual models. Each item was mapped
where it was considered to reflect the concept, meaning
that items could be mapped to more than one concept
if deemed appropriate. Partial coverage was also consid-
ered, and items that partly covered concepts were
mapped and indicated in brackets.
Results
Literature Review Part 1: Qualitative Research
The study selection process for part one of the literature
review is presented in Figure 1.
Patients Subjective Experiences with Type 2 Diabetes
Review of these studies revealed that aches and pains
[23-25], hunger [23,26], thirst [23,26], tiredness
[23,26,27], lack of energy [23,28,29], as well as dizziness
[24,26] are prominent symptoms for patients with type
2 diabetes. Type 2 diabetes and associated symptoms
were perceived to influence HRQoL in relation to
physical functioning [23,30-33], role functioning
[26,29,30,34-38], activities of daily living [23,27,32,39,40],
mental health and mood [24,27,29,30,36,39,41-45], emo-
tional functioning [23,25-27,30,31,34,36-38,40,41,44,
46-54], relationships [27,31,32,41,49,55,56], sexual func-
tioning [42,48,55], social functioning [27,31,32,37,41,42]
and self image [23,29,31,33,42,44,47,51,53,57,58]. Table 2
provides example quotes to illustrate each of these
concepts.
Patients Subjective Experiences with Alzheimer’s Disease
Symptoms experienced by patients were mainly related
to short term memory loss [59-63] and included loss of
words and thought. In contrast to this there was a sense
of physical well being [60,61,64,65]. The influence of
AD and its associated symptoms focused on activities of
daily living [59-61,63-68], mental health [59,64-68] and
emotional functioning [59-61,63-65,67], relationships
[61,63-65,68], independence [59-62,64,68], social func-
tioning [59,61,63-65], role functioning [63,68] and self
image [59,61,63,68]. Table 3 provides example quotes to
illustrate these concepts.
A review of the concepts of relevance to both patients
with type 2 diabetes and AD indicate that there are a
number of concepts that the two disease areas have in
common such as activities of daily living, role function-
ing, emotional functioning, mental health, relationships,
social functioning, and self image. However there are
concepts that are relevant to type 2 diabetes such as
sexual functioning that were not highlighted as relevant
to AD patients, conversely patients with AD were
greatly impacted by the loss of their independence
where type 2 diabetes patients did not mention this.
Finally the key symptoms of each disease were also
quite different (fatigue in type 2 diabetes vs. memory
loss in AD). Thus, this evidence highlights that while
some disease areas do have common concepts there are
also important concepts that may differ highlighting a
potential lack of sensitivity when measuring utilities
using a generic instrument.
Literature Review Part II: Utility Measures
The additional literature search generated 160 abstracts.
The titles and abstracts were reviewed and a total of
145 were excluded due to the search terms not being in
the title or abstract, due to duplication between data-
bases or the search terms were not the main focus of
the article. A total of 15 articles were reviewed in full.
Although no disease-specific utilities were identified, the
following generic measures were used in both
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2 and 3). A comparison of the content and measure-
ment properties of these measures is described below.
EQ-5D
The EQ-5D was developed as a generic, HRQoL instru-
ment designed to assess health outcome states across a
wide variety of interventions on a common scale [13].
W h i l eh e a l t h yp e o p l ew e r ei n v o l v e di na ne x e r c i s eu s i n g
a VAS and a TTO to develop the utility scores, no one
was interviewed to ascertain which concepts should be
included as a comprehensive assessment of HRQoL. The
instrument was developed based on a review of existing
literature and health status measures at the time [69].
The EQ-5D index is classified according to five dimen-
sions: mobility, self care, usual activities, pain and mood.
There is one additional item where health state “today” is
compared with general level of health over the past
twelve months. There is also a VAS scale where the cur-
rent health status is rated on a scale from 0 (worst ima-
ginable health state) to 100 (best imaginable health state).
15D
The 15D was developed to measure HRQoL and its uti-
lity, and to evaluate the efficacy and effectiveness of
interventions [11]. It was developed based on a review
of existing literature and instruments and also involved
health care professional input. Values were derived
based on surveys using the general population [69]. It is
a generic fifteen item instrument: mobility, vision, hear-
ing, breathing, eating, sleeping, speech, elimination,
usual activities, mental function, discomfort and symp-
toms, depression, distress, vitality and sexual activity.
SF-6D
The SF-6D was developed as a simplified health state
classification from the SF-36/SF-12 [12] which was
developed based on literature and instrument review but
did not involve patient or general population input in its
development. Values however were generated based on
i n p u tf r o mt h eU Kg e n e r a lp o p u l a t i o n[ 6 9 ] .I ti sa
generic measure designed to assess HRQoL across age,
disease and treatment groups. The SF-6D includes 6
1022 abstracts located 
839 abstracts excluded: search terms not in 
838, 1 duplicated 
183 abstracts 
126 abstracts excluded 
following ranking 
57 articles reviewed 
10 Alzheimer’s disease 
articles 
38 Diabetes mellitus, type 
2 articles 
9 articles excluded 
following review 
Figure 1 Inclusion and Exclusion of Studies.
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Concept Sub concept Example quote
Symptoms Tiredness This morning I had a hard time just getting out of bed. I was so tired. Very very tired [27]
Sweaty Your body talks back to you...it reminds me. A lot of time I feel the diabetes is when it’s low. I get sweaty, hot
and hungry [23].
Thirst I used to feel thirsty at night time, but I used to think it was probably...because I had a very bad heating
system...”[26]
Hot Your body talks back to you...it reminds me. A lot of time I feel the diabetes is when it’s low. I get sweaty, hot
and hungry [23].
Hunger Your body talks back to you...it reminds me. A lot of time I feel the diabetes is when it’s low. I get sweaty, hot
and hungry [23].
Aches and
pains
That’s another meaning of diabetes - getting headaches, dizziness and body aches[24]
Lack of energy In the morning my energy runs out because my sugar is too low; in the evening it runs out because it is too
high[23]
Dizziness I think it was like feeling dizzy, using the bathroom a lot, tired [26].
Emotional
Functioning
Embarrassment I am ashamed to do it [insulin therapy]. What will others think - that I am a drug addict or
something?! [51]
Frustration I also have two small children and that’s a problem...they don’t like eatin’ the way I eat...I get frustrated...” [34].
Anger It’s the diabetic anger and people will not understand it...it’s out of proportion with the event.” [27]
Mental health Anxiety There are times when I’m here at home alone and I get so anxious as I start to think, ‘I don’t want to think
about eating,’ but it’s the only thing on my mind - eating, eating, eating....and I start to cry because what’s
inside I know I cant eat [27].
Depression Sometimes, knowing that I am diabetic and that I am limited, sometimes if I’m not careful, it can cause
depression[56]
Relationships Partner My husband does not want to pay attention and refuses to eat less salt and more vegetables and says the diet
is disgusting[55]
Friends All of my friends, every time I run into one of them, the first thing they ask me is ‘how’s your diabetes?’ Here I
am trying to forget about my diabetes for a little while, and they remind me of it constantly [27].
Family Taking care of the kids. I want to have energy for them. You know I take them to the park and they want to
play and I don’t have enough energy to get up and play with them... [30]
Sexual
Functioning
Activity You get your tired periods, but...you just rest and then you’re okay again. I don’t have sex as much ‘cos I’m tired
more. [42]
Desire My sexual appetite was diminished. [42]
Mental arousal You’re not turned on the same...you yearn for the feelings...but they’re just not there[42]
Social Impact Vacation/
holidays
I cant do half of the things I used to...you cant go on vacations with people like you used to because you cant
keep up with them...so I stay at home a lot. So then the depression - the whole circle starts again. [31]
Socialising It wasn’t like that before diabetes. No I had a very active social life. I used to go to parties, I went out a lot - all
the things someone normally does in his life. Now, I’m always tired. [27]
Constraints It puts time constraints on us...you’re not just free to go out and have a day out to yourself. [31]
Role Functioning Work I want to go to work and I don’t think I can manage a whole day of work. [30]
Yeah, I guess I was tired. In fact I had a second job I had to stop doping it I was so tired. [26]
Physical
Functioning
Activities It makes me feel old, wasted. I use to go dancing every weekend. I wouldn’t stop dancing. If I go to the dance
hall, I would dance all the time and now, I cannot[30]
Self Image Self concept I am ashamed to do it. What will the others think - that I am a drug addict or something?! [51]
I felt a bit like Frankenstein. I’m injecting someone here! You start looking at yourself more in the mirror and
thinking Am I changing? [53].
Activities of Daily
Living
Self care You’re always spilling urine, and that is too embarrassing. And you’re never clean[23]
Shopping And you’re never clean. That’s why you can’t go shopping...You know how to try on clothes[23]
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functioning, pain, mental health and vitality.
Health Utilities Index (HUI)
The HUI consists of three systems: HUI Mark 1 (HUI
1 ) ,M a r k2( H U I2 )a n dM a r k3( H U I3 )[ 1 0 ] .H U I2
and HUI 3 are more frequently used and so have been
included in this review. The HUI was developed to
describe health status, measure within-attribute morbid-
ity and HRQoL, as well as to produce utility scores. The
HUI 2 system appears to have been developed based on
theory and literature review and a survey of parents; and
the general population were involved in the develop-
ment of valuation scores [69]. The HUI 2 includes seven
attributes: sensation, mobility, emotion, cognition, self
care, pain and fertility. The HUI 3 includes eight
attributes: vision, hearing, speech, ambulation, dexterity,
emotion, cognition and pain. Both are generic
instruments.
Mapping PRO Conceptual Models to Utility Instruments
Based on the qualitative results, Figure 2 and Figure 3
provide proposed conceptual models of type 2 diabetes
and AD, respectively. The individual items of the gen-
eric utility instruments were then mapped on to the
proposed conceptual models. Findings showed that
although there were many relevant instrument items,
none of the generic utility measures covered all the rele-
vant concepts important to patients with type 2 diabetes
or AD. The 15D seemed to be the most comprehensive
measure for both type 2 diabetes and AD. The HUI 3
seemed to have the least coverage for the type 2
Table 3 Example quotes for AD concepts
Concept Sub concept Example quotes
Symptoms Memory loss I can look up somebody’s name, go to the phone book, once I’ve got the number, I’ve forgotten whose name
I’m looking for [61]
Loss of thought This is the worst part when I lose my train of thoughts and you stand there like an idiot! It gets a little
embarrassing[61]
Emotional
Functioning
Anger The worst thing is my short term memory, which irritates me so much. I get angry with myself. [65]
Fear Well, that part is a little frightening when all of a sudden you find yourself, you know, what do I do? Like
where am I? or what[61]
Mental Health Anxiety It’s kind of scary to me...and I’ll hate going out or anything. [61]
Relationships Partner She wants to help and sometimes she overhelps and I have to say, you know, just leave me, and she gets a
bit cross... [59]
Friends No...my intimate friends possibly, but I don’t talk that much about it...this is my concern, and I will sort it out
because it afflicts me, me and my family. But our neighbours know[65]
Family My family members’ relationships with me changed as soon as they found out I was ‘no longer competent.’
The things that I say seem to be a lot more subject to question than they used to be. It’s as if I cant possibly
know anything anymore[68]
Social Impact Socialising Well, all of a sudden I felt a wave of terror wash over me. We went in and it turned out to be a surprise party.
Well, I didn’t recognize anyone...it was then that I got overcome and passed out. It was the worst experience I
can tell you. [63].
Conversation I’m ducking out of conversations more. [64]
Withdrawal Yeah, another bad thing that I find now, that I don’t want to speak to anybody in here (meaning the housing
complex). Because I can’t talk to them soon as they talk...I know everybody. But their names are all gone. [61]
Physical
functioning
Physical well
being
I’m so happy that I’m physically well. So...so I make sure I’m out and about a lot. [65]
Activities of Daily
living
Activities As for driving the car, I used to like it...but now I have to get in a car with someone else and tell them where I
want to go[68]
I can look up somebody’s name, go to the phone book, once I’ve got the number, I’ve forgotten whose name
I’m looking for...[61]
Self care I can’t do anything myself. Even buttons and things like that...I just...they do it for me...I hate these things. I get
the temper. [64]
Hobbies I think it started with the sewing. People would ask me to sew something for them and I’d forget all about it
[63].
Self Image Self concept It’s devastating, and it takes away your sense of self. And I find it very hard to deal with [63]
Independence Loss of
independence
Your neighbours will stop and talk to you, just for a minute. Then they’ll say, ‘well I’ll walk around with you.’
And I wish I’d never told them I have it because it took away my freedom. [68]
Role Functioning Work I used to teach classes. I used to edit a journal. I used to do all kinds of things I’m not doing now[68]
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TREATMENT 
 Oral  medication 
 Insulin  tablets 
 Insulin  injections 
  Insulin and oral combination 
 
Self management: 
 Exercise 
 Diet 
 Glucose  Monitoring 
 
Combined: 
  Diet plus oral hypoglycaemic agents  
 Diet  plus  insulin 
 Diet,  insulin  and  Pills 
TYPE 2 DIABETES  INDIVIDUAL 
CHARACTERISTICS 
 Age   
 Gender 
 Ethnicity 
 Culture 
SYMPTOMS 
 
 Drowsiness    ● 
  Tiredness  ●■ 
 Weakness    (●) 
 Headaches   
 Dizziness   
 Mouth  problems   
 Pain  ●♠♦▲■ 
 Body  aches  ● 
 Physical  discomfort  ●♠ ♦▲ 
 
 Excessive  thirst   
  Excessive /frequent urinating 
 Incontinence ● 
 Sweating 
 Hot   
 Hunger   
 Lack  of  energy    ●■ 
SIGNS
  High blood sugar  
 Overweight   
COMPLICATIONS AND 
COMORBIDITIES 
 
 Peripheral  neuropathy    ♦▲●■ ♠ 
 Strokes   
 Kidney  problems   
 Cardiovascular   
          - Hypertension  
          - Hypercholesterolemia  
 Impotence    ● 
 Retinopathy    ● ▲♦
 Hypoglycemia    ●■
EXTERNAL FACTORS 
 Stressful  events 
 Health  care  providers 
 Provision  of  information 
 Family  environment/stress 
 Economic  issues 
 Environment 
 Diagnosis 
 Coping   
Key: 
● = 15D 
♠ = EQ-5D 
♦ = HU12  
▲ = HU13 
■ = SF-6D 
 
Physical 
Functioning/ 
Mobility ● ♠♦▲■ 
 Sport   
 Exercise   
 Activities   
Role Functioning  
 Physical  ●■ 
 School  ♠● 
 Work   ♠● ■  
Activities of Daily Living 
 Self  care   ♠♦■ 
 Daily  routine  ♠● ■ 
 Shopping   
 Driving   
 
Relationships (13) 
 Colleagues   
 Friends   
 Partner   
 Family   
 Teachers/Peers   
Social Impact ■ 
 Socialising 
 Vacations 
Sexual Functioning 
 Activity  ● 
 Desire   
 Mental  arousal   
Emotional Functioning  
 Embarrassment   
 Fear 
 Frustration   
 Despair   
 Sadness    ●▲■ 
 Irritation   ♦ 
 Anger   ♦ 
 Shame   
 Concern  about  the  future   
 Happiness   ♦▲ 
 Relief   
Mental Health  
 Anxiety    ● ♠♦ 
 Stress  ● 
 Depression  ●■♠♦▲ 
 Worry   ♦ 
 Mood   ■ ● 
Type II Diabetes Management 
 Diet   
  Treatment regime  
 Control/Restriction   
 Adherence   
 Time   
Vitality  
 Fatigue   
 Low  energy    ■● 
 Feeling  tired   ● 
Self Image 
  Self esteem  
  Body and self image  
 Self  worth 
 Self  concept   
 Self  blame 
 Powerlessness   
Figure 2 Impact of Patients with Type 2 Diabetes.
 
 
 
 
 
ALZHEIMER’S DISEASE 
COMPETENCIES 
 Driving 
 Cooking 
 Counting/adding  up  money 
  Paying the bills 
INDIVIDUAL CHARACTERISTICS 
 Gender 
 Stage  of  Alzheimer’s  disease 
EXTERNAL FACTORS 
 Marital  status 
 Residential  status 
 Environment 
 Coping   
SYMPTOMS 
 Memory  loss  ●▲ (♦) 
 Short  term  memory  loss  ● 
  Difficulties with word finding  (●)  
 Disorientation  ● 
 Easily  distracted 
 Wandering 
  Unable to think quickly 
 Counting  difficulties 
 Loss  of  thought   ●▲ 
SIGNS
 Cognitive  decline  ▲● (♦) 
 Memory  impairment  ●▲ 
 Visuospatial  disability 
 Psychomotor  retardation 
 Dysphasia 
Incompetence
 Self  perceived 
 Perception  of  others   
Role Functioning 
 Physical  ●■ 
 Work  ●■ ♠ 
Physical Functioning ●
♠ ♦▲■ 
Physical well being 
Activities of Daily Living 
 Self  care  ♦■♠ 
 Daily  activities  ♠■● 
 Hobbies  ♠● 
 Finances 
Relationships 
 Children 
 Neighbours 
 Family 
 Partners 
 Friends 
Independence 
 Dependence    (▲♦●) 
 Loss  of  independence 
  Loss of freedom  
Key: 
● = 15D 
♠ = EQ-5D 
♦ = HU12  
▲ = HU13 
■ = SF-6D 
Mental Health  
 Mood ■● 
 Suicidal  ideation  ▲ 
 Depression  ●♠ ♦▲■ 
 Anxiety/worry  ●♠♦ 
Emotional Functioning  
 Overwhelmed 
 Fear 
 Sadness  ●■▲ 
 Despair 
 Bad  tempered  ♦ 
 Frustration 
 Anger  ♦ 
 Disgust 
 Embarrassment 
 Shame   
Social Impact ■ 
 Socialising 
 Withdrawal 
 Conversation/interaction  (●▲) 
 Social  isolation 
Self Image 
 Self  concept 
 Self  worth 
 Status  /Role 
 Uselessness   
Figure 3 Impact of Patients with Alzheimer’s Disease.
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Page 8 of 13diabetes conceptual model, and the EQ-5D for the AD
conceptual model. The HUI 3 and EQ-5D do not have
items relating to relationships, sexual functioning or
social impact; all of which emerged as relevant concepts
important to patients with type 2 diabetes. Similarly, the
EQ-5D does not have items relating to cognitive func-
tioning, social impact or relationships; concepts of
relevance to patients with AD.
Further, some of the utility instruments contained
items that could not be mapped onto either of the pro-
posed conceptual models. For example, the ‘hearing,’
‘breathing’ and ‘sleeping’ items from the 15D did not
appear to be relevant to either indication which could
lead to potential problems such as missing data or lack
of sensitivity for these measures when included in a
clinical trial.
Discussion
In general, the findings from our study have demon-
strated there was incomplete and varied coverage of
relevant concepts across specific disease areas, with dis-
parities varying depending on the disease in question.
There were also differences in the concepts covered
within the generic utility measures discussed. Both find-
ings point to a potential lack of consistency between
measures.
An evaluation of the utility instruments needs to take
into account three issues: relevance of concepts to the
general population, such as whether a concept specific
to a disease would resonate and be relevant to a healthy
individual, relevance of concepts to the patient popula-
tion being assessed and comprehensiveness of the con-
cepts included in the questionnaire from the patient and
general population perspective.
To our knowledge, the general population did not rate
or rank which concepts were the most important to
include in the four utility instruments assessed. All of
the concepts included in the utility instruments were
based on literature and instrument reviews, rather than
using input from patients or the general population.
The four instruments also differed in the concepts that
were covered. It would be unrealistic to expect that a
generic instrument cover each and every concept that is
of importance to the general population. However, some
concepts that are important to patients may also be
important to the population at large. Our results for the
diabetes population suggest that tiredness, sexual func-
tioning, social or family impact, and work impact are
key concepts that are not covered by many of the utility
scales but are likely to be important to the general
population. Similarly, cognition and independence are
important concepts to AD patients and are likely to be
important to the general population. Brazier et al have
already demonstrated in some diseases that leaving out
concepts considered relevant to patients can result in
under representation of relevant health impact in the
QALY and over estimation of the cost per QALY [69].
Further testing of these assumptions is warranted in
other important diseases such as AD and diabetes.
A detailed calibration of these instruments (as per
Brazier et al) in AD and diabetes was beyond the scope
of this study. However, the concept mapping illustrates
the challenges in representing the diseases optimally and
in a way that allows comparison with other diseases. It
also raises some philosophical questions about how the
content of utility measures should be decided upon.
Some instruments may be weighted toward concepts
that are of no relevance to the patient population being
studied. For example, in our review, patients with AD
reported being physically healthy, but the EQ-5D has a
preponderance of items that cover physical health (pain,
mobility, self-care, usual activities). This leaves only one
item (depression) that may be relevant to AD patients
and completely omits the key AD concepts of memory
and independence. Thus, it is likely that in any eco-
nomic analysis of current AD drugs that use the EQ-5D
as the primary utility measure, the results will only
allow assessment of the impact of treatment on depres-
sion thereby under representing the full utility of treat-
ment. One could argue that the concepts covered are
relevant to the general population and therefore allow
for more accurate economic analyses. Yet, it could also
be argued that cognition and independence are impor-
tant concepts to the general population as well as to AD
patients, so those concepts perhaps should have been
included in a generic utility measure (as indeed they are
represented in the 15D and HUI).
It can also be questioned whether it is possible to
measure healthy people and people with a relevant dis-
ease using the same measure. Qualitative research such
as focus groups or in-depth interviews with members of
the public that represent typical diseases in the general
population should be conducted to ascertain the con-
cepts that are most relevant to include in a HRQL utility
measure. This could be considered in the development
of reference utility measures. This is in line with recent
guidance from reimbursement bodies who suggest that
qualitative evidence is also important when valuing utili-
ties. Qualitative evidence provides unique insight into
the disease from the patient who has experienced the
symptoms and impacts of the disease first hand. This is
supported by NICE who state ‘Patients and carers are a
unique source of expert information about the personal
impact of a disease and its treatment’ [3].
These findings are consistent with previous research.
For example, one study compared three generic utility
based measures (EQ-5D, SF-6D and HUI 3) in age-
related macular degeneration (ARMD) [70]. Results
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Page 9 of 13indicated that the impact of age-related macular degen-
eration was not well reflected in the EQ-5D or SF-6D
with mean utility values of 0.72 (standard deviation =
0.22) and 0.66 (standard deviation = 0.14) respectively.
With regard to the HUI 3, which contains a vision
domain, this was considered to better reflect the visual
functioning impact; with a mean utility value of 0.34
(standard deviation = 0.28) it had a larger and more sig-
nificant correlation with tests of visual function than the
other preference-based measures.
Other studies also provide evidence to support how
the choice of method for utility elicitation may lead to
difference in utility assessments. For example; one study
compared the SF-6D with the EQ-5D and found that
there was agreement between both utility instruments
demonstrating evidence of validity. However on closer
reflection utility results varied, with EQ-5D scores being
significantly higher in healthy populations, and SF-6D
scores being significantly higher in disease samples, thus
pointing to differences in scaling and a lack of calibra-
tion between utility measures [71].
Further, a literature review of studies in a variety of
disease areas (including but not limited to patients with
hearing impairment, spine disorders, rheumatic diseases)
that compared preference based systems found that the
EQ-5D showed larger change scores and more favorable
cost-effectiveness ratios compared to the HUI 2 and
HUI 3 [72] and the SF-6D.
The results from these studies and supporting evi-
dence are pertinent given that generic utility measures
are documented as the preferr e do p t i o ni nr e i m b u r s e -
ment guidance documents [3-6] and that they are used
by national, regional and local key stakeholders in Eur-
ope to facilitate decision making regarding allocation of
resources across competing interventions. Such findings
point towards a need to take in to greater account the
patient perspective and relevant concepts as part of the
input to decision-making.
Our study has a number of possible limitations that
deserve comment. This study was based on published
literature, most of which the purpose was not to assess
impact on HRQoL. In addition, the literature search was
restricted to English language studies and MeSH terms
were used when available. MeSH terms were not avail-
able for all search terms. Therefore valuable information
could have been missed and there may still remain
some concepts of importance.
The proposed conceptual models of impact were
developed based on existing qualitative research that
had been carried out and was from the patient perspec-
tive. Consequently, they have not been supplemented
with patient interviews to confirm that the proposed
areas of impact are indeed important and relevant to
patients and put in the context of a specific treatment
of study. Having said that, the volume of available infor-
mation was encouraging as a resource. Additionally, we
have limited this study to two indications and the rele-
vant concepts may be very different for others. Further
research could explore the relevance of utility instru-
ments in other indications and in the general
population.
Also the very nature of AD means that less patient
reported information is available, and many studies rely
on caregiver reports. The patient reported information
that is available is primarily from mild to moderate AD
patients and so the proposed models may be reflective
of this. Thus the proposed model may be a reflection of
the earlier stages of the condition and not the disease in
its entirety.
There were other disease associated factors which may
influence patients’ experiences with their disease. Some
studies commented on the added impact of being
diagnosed with and the management of diabetes if in an
ethnic minority. Diabetes management itself emerged as
a seemingly relevant associated factor. Coping strategies
appeared to weigh heavily in AD and these included
very practical adaptive techniques like using aide mem-
oirs and writing things down, and the use of humour
and laughing to cope with the emotional strain asso-
ciated with the daily hassles of forgetting. Other external
factors included age, gender, culture and environment.
These other factors may influence the patients’ experi-
ence with a condition and may have an interactive role
in the proposed conceptual models that have been
developed from the literature; however such factors
would also be controlled for, and taken into account in
a clinical trial setting.
A further aspect of the development of future utility
instruments is that the dominance of the QALY in the
use of HTA and economic evaluation could be reduced
by the use of alternative instruments or methods of
measurement. Agencies such as the Institute for Quality
and Efficiency in Health Care (IQWiG) in Germany and
discussions at recent HTA conferences have been con-
sidering the use of alternative methods for decision
making. Therefore if the QALY is to retain its place as a
key method for the use of cost-effectiveness for decision
making across countries generic measures need to be
constantly improved. Including the patient perspective
in development of future instruments and the further
development of existing instruments could be a first
step aiding the continual improvement of such
instruments.
Conclusions
Despite the limitations of this study, the findings
illustrate the potential value of considering qualitative
information in the interpretation of cost utility estimates
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Page 10 of 13and the need to include more qualitative research in the
design of not only the next wave of utility instruments,
but also in the further development of existing instru-
ments such as the EQ-5D.
Content of the utility measures has a significant
impact on the treatment effects that can be observed
and currently in choosing a generic utility measure
there appears to be a tradeoff of content in order to
achieve consistency. The amount of patient relevant
information missing from the chosen generic measures
varies from one indication to another, which provides,
and could continue to provide a source of inconsistency
between the measures. Likewise, the variability in con-
cepts across the generic measures suggests lack of con-
sistency even for general population research, suggesting
that the potential impact and importance of content is
presently under represented. With current reporting
standards, we cannot know the size of this tradeoff
between content and consistency and its contribution to
the variance in utility findings. This issue would remain
if the proposed solution of a “reference method” [21] for
all economic evaluations was realised. Thus we propose
that a content map of the chosen utility measure with
patient-reported domains be provided as standard
reporting in cost utility measurement in order to
improve the transparency of the trade-offs in relation to
patient relevance and consistency.
Patient’s perspectives using qualitative methods should
be adopted and feature in the decision-making methods
used by reimbursement bodies so that there are clearly
defined criteria. This movement has the attraction of
reducing the scope for controversial decisions based on
utility estimates. It could also serve as a bridge to the
methods endorsed by regulatory authorities such as the
Food and Drug Administration (FDA) and European
Medicines Agency (EMA) [16,17] and allow for better
continuity of knowledge about treatment effects.
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